NASDAQ:CERT - Certara Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.40
  • Forecasted Upside: 41.03 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$25.81
▼ -0.56 (-2.12%)
1 month | 3 months | 12 months
Get New Certara Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CERT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CERT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$36.40
▲ +41.03% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Certara in the last 3 months. The average price target is $36.40, with a high forecast of $41.00 and a low forecast of $33.00. The average price target represents a 41.03% upside from the last price of $25.81.
Buy
The current consensus among 6 polled investment analysts is to buy stock in Certara. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2021Morgan StanleyLower Price TargetEqual Weight$35.00 ➝ $33.00High
i
3/8/2021BarclaysInitiated CoverageOverweight$40.00N/A
i
3/5/2021William BlairReiterated RatingOutperformHigh
i
Rating by J. Kreger at William Blair
3/2/2021BarclaysInitiated CoverageOverweight$40.00High
i
1/5/2021Morgan StanleyInitiated CoverageEqual Weight$35.00N/A
i
1/5/2021Jefferies Financial GroupInitiated CoverageHold$33.00N/A
i
1/5/2021Credit Suisse GroupInitiated CoverageNeutral$35.00N/A
i
1/5/2021William BlairInitiated CoverageOutperformN/A
i
Rating by J. Garro at William Blair
1/5/2021Bank of AmericaInitiated CoverageBuy$41.00N/A
i
(Data available from 3/8/2016 forward)
Certara logo
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies and academic institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $25.81
$25.23
$28.05

50 Day Range

MA: $36.17
$30.52
$39.00

52 Week Range

Now: $25.81
$25.50
$41.79

Volume

17,584 shs

Average Volume

471,475 shs

Market Capitalization

$3.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Certara?

The following Wall Street sell-side analysts have issued stock ratings on Certara in the last year: Bank of America Co., Barclays PLC, Credit Suisse Group AG, Jefferies Financial Group Inc., Morgan Stanley, and William Blair.
View the latest analyst ratings for CERT.

What is the current price target for Certara?

5 Wall Street analysts have set twelve-month price targets for Certara in the last year. Their average twelve-month price target is $36.40, suggesting a possible upside of 29.8%. Bank of America Co. has the highest price target set, predicting CERT will reach $41.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $33.00 for Certara in the next year.
View the latest price targets for CERT.

What is the current consensus analyst rating for Certara?

Certara currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CERT will outperform the market and that investors should add to their positions of Certara.
View the latest ratings for CERT.

What other companies compete with Certara?

How do I contact Certara's investor relations team?

Certara's physical mailing address is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. The company's listed phone number is 609-716-7900. The official website for Certara is www.certara.com.